SCHEMBL301712

SCHEMBL301712

O=C(NC1CCC1)c1cccc(N(Cc2ccc(Cl)cc2)S(=O)(=O)c2cccnc2)c1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 3/20 0.52
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
SPR P35270 1/20 0.47
ALDH1A1 P00352 2/20 0.46
LMNA P02545 2/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
PSEN1 P49768 2/20 0.45
PSEN2 P49810 2/20 0.45
APH1B Q8WW43 2/20 0.45
NCSTN Q92542 2/20 0.45
APH1A Q96BI3 2/20 0.45
PSENEN Q9NZ42 2/20 0.45
HSD17B10 Q99714 1/20 0.45
PKM P14618 1/20 0.45
HSD11B1 P28845 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2186628 0.98 GRM5 (0.49) GRM5MEN1KMT2ASPRALDH1A1
SCHEMBL307512 0.97 GRM5 (0.48) GRM5MEN1KMT2ASPRALDH1A1
SCHEMBL2188728 0.96 SPR (0.49) GRM5MEN1KMT2ASPRALDH1A1
SCHEMBL2209547 0.86 LMNA (0.43) GRM5KMT2ASPRALDH1A1LMNA
SCHEMBL2246857 0.85 MEN1 (0.65) MEN1KMT2AALDH1A1LMNAHTT
SCHEMBL303264 0.85 LMNA (0.51) MEN1KMT2AALDH1A1LMNAHTT
SCHEMBL3379160 0.85 LMNA (0.49) MEN1KMT2AALDH1A1LMNAHTT
SCHEMBL2209550 0.85 GRM5 (0.38) GRM5MEN1KMT2ASPRLMNA
SCHEMBL302902 0.83 LMNA (0.51) MEN1KMT2AALDH1A1LMNAHTT
SCHEMBL301955 0.83 LMNA (0.49) MEN1KMT2ALMNAHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP claimed
US-9447033-B2 Potassium channel blockers JAPAN TOBACCO INC. (JP) 2016-09-20 US claimed
US-20150259282-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2015-09-17 US claimed
US-20140221337-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2014-08-07 US claimed
JP-2012500836-A 2012-01-12 JP claimed
EP-2342177-A1 NOVEL POTASSIUM CHANNEL BLOCKERS Xention Limited (GB) 2011-07-13 EP claimed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
WO-2010023448-A1 NOVEL POTASSIUM CHANNEL BLOCKERS XENTION LIMITED (GB) 2010-03-04 WO claimed
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP disclosed
US-9447033-B2 Potassium channel blockers JAPAN TOBACCO INC. (JP) 2016-09-20 US disclosed
US-20150259282-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2015-09-17 US disclosed
US-9073834-B2 Potassium channel blockers XENTION LIMITED (GB) 2015-07-07 US disclosed
US-20140221337-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2014-08-07 US disclosed
US-8673901-B2 Potassium channel blockers XENTION LIMITED (GB) 2014-03-18 US disclosed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221337-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 GRM5 841/4885MEN1 608/4885KMT2A 386/4885
US-20100087428-A1 Novel Potassium Channel Blockers HCN4, SCN2B, KCNH2 GRM5 297/4885MEN1 2747/4885KMT2A 1511/4885
US-20150259282-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 GRM5 841/4885MEN1 608/4885KMT2A 386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.